Applied Cannabis Research is pleased to advise that it has received ethics approval to undertake a study of medicinal cannabis in sufferers of Post Traumatic Stress Disorder (PTSD).
Patient recruitment for the landmark 12 month trial will be facilitated by the Cannabis Access Clinics network.
PTSD is a particular set of reactions that can develop in people who have experienced a traumatic event which threatened their life or safety. As a result, sufferers develop feelings of intense fear, helplessness and horror. It is estimated PTSD affects 12% of Australians.
Participants in the study will receive medicinal cannabis extract ECs315 from product supplier BOD Australia. Patients will bear standard treatment costs for participating in the study, although they will be eligible for rebates through Medicare and, in some cases, private insurers.
Dr John Barlow, principal researcher at Applied Cannabis Research
